Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cleve Clin J Med. 2004 Aug;71(8):609-16.

Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients.

Author information

  • 1Division of Cardiology, Department of Medicine, University of California, San Francisco 94143, USA. kkhush@medicine.ucsf.edu

Abstract

The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.

PMID:
15449756
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk